Search
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational[A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexNavitoclax
go.drugbank.com/drugs/DB12340InvestigationalNavitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer.
Synonyms: (R)-4-(3-Morpholin-4-Yl-1-Phenylsulfanylmethyl-Propylamino)-N-(4-{4-[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-Enylmethyl]-Piperazin-1-Yl}-Benzoyl)-3-TrifluoromethanesulfonylbenzenesulfonamideSotrastaurin
go.drugbank.com/drugs/DB12369InvestigationalSotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Synonyms: (R)-2-(4-((2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)-THIO)-2-METHYLPHENOXY)ACETIC ACID, ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACIDCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRemimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[L14647] Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as [remifentanil], are designed to be metabolically fragile and thus … [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.
Categories: Heterocyclic Compounds, 2-RingNadifloxacin
go.drugbank.com/drugs/DB12447InvestigationalNadifloxacin has been used in trials studying the treatment of Acne Vulgaris.
Categories: 4-Quinolones, Heterocyclic Compounds, 2-RingProducts: MAGNIS %1 KREM ,30 G, AKNEFLOKS %1 KREM, 30 GRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. … [A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore
Categories: MATE 1 Inhibitors, P-glycoprotein substratesFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. … [A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. … In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity is lower.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesBatefenterol
go.drugbank.com/drugs/DB12526InvestigationalBatefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Categories: Heterocyclic Compounds, 2-Ring, Adrenergic beta-2 Receptor Agonists